Details about Lionel Perrier

Access statistics for papers by Lionel Perrier.

Last updated 2022-08-09. Update your information in the RePEc Author Service.

Short-id: ppe847

Working Papers

2023

1. Connected device and therapeutic patient education to promote physical activity among women with localised breast cancer (DISCO trial): protocol for a multicentre 2×2 factorial randomised controlled trial
   Post-Print, HAL

2022

2. What underlies the observed hospital volume- outcome relationship?
   Post-Print, HAL
   Also in Post-Print, HAL (2017)
   Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon (2018)

2021

3. Challenges raised by the economic evaluation of CAR-T-cell therapies. The review by the French National Authority for Health
   Post-Print, HAL View citations (1)
4. Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors
   Post-Print, HAL
5. Determinants of the need for respite according to the characteristics of informal carers of elderly people at home: results from the 2015 French national survey
   Post-Print, HAL
6. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)
   Post-Print, HAL
7. How much does the hospital stay for infusion of anti-CD19 CAR-T cells cost to the French National Health Insurance?
   Post-Print, HAL
8. Interpretable Machine Learning Model for Locoregional Relapse Prediction in Oropharyngeal Cancers
   Post-Print, HAL
9. Value based healthcare et donnée de vie réelles/SNDS en radiothérapie
   Post-Print, HAL

2020

10. A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study
    Post-Print, HAL
11. Chronic Low-Dose Exposure to Xenoestrogen Ambient Air Pollutants and Breast Cancer Risk: XENAIR Protocol for a Case-Control Study Nested Within the French E3N Cohort
    Post-Print, HAL
12. Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial
    Post-Print, HAL View citations (1)
13. Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
    Post-Print, HAL View citations (3)
    See also Journal Article Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review, PharmacoEconomics, Springer (2020) View citations (1) (2020)
14. Coût du programme d’éducation thérapeutique « Mieux manger, mieux bouger à l’aide de l’éducation nutritionnelle » chez les patientes atteintes d’un cancer du sein
    Post-Print, HAL
15. Impact of Next Generation Sequencing on Clinical Practice in Oncology in France: Better Genetic Profiles for Patients Improve Access to Experimental Treatments
    Post-Print, HAL

2019

16. Apport de la génomique dans la médecine de demain, applications cliniques et enjeux
    Post-Print, HAL
17. Cost-utility analyses of interventions for informal caregivers: A systemic and critical review
    Post-Print, HAL
18. Critical review and quality-assessment of cost analyses in radiotherapy: How reliable are the data?
    Post-Print, HAL
19. Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial
    Post-Print, HAL
20. Financial impact of innovation in Oncology
    Post-Print, HAL
21. Impact d’une centralisation des soins en termes d’accès aux soins pour les cancers de l’ovaire et cancers du sein en France: une simulation à partir des données médico-administratives
    Post-Print, HAL
22. Impact financier de l’innovation en oncologie
    Post-Print, HAL
23. National costs and resource requirements of external beam radiotherapy: A time-driven activity-based costing model from the ESTRO-HERO project
    Post-Print, HAL
24. Optimisation du parcours de soins dans la prise en charge initiale des cancers épithéliaux ovariens en France
    Post-Print, HAL

2018

25. Being Treated In Higher Volume Hospitals Leads To Longer Progression-Free Survival For Epithelial Ovarian Carcinoma Patients in the Rhone-Alpes region of France
    Post-Print, HAL View citations (4)
26. Challenges in the value assessment, Pricing, and funding of targeted combination therapies in oncology
    Post-Print, HAL
27. Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study
    Post-Print, HAL View citations (1)
28. In reply to Jean-François Daisne, Sandra Nuyts, Fréderic Duprez and Benoît Bihin
    Post-Print, HAL
29. In reply to Tallet et al
    Post-Print, HAL
30. Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation
    Post-Print, HAL View citations (1)
    See also Journal Article Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation, Health Care Management Science, Springer (2018) View citations (1) (2018)
31. Systematic Screening for Occupational Exposures in Lung Cancer Patients: A Prospective French Cohort
    Post-Print, HAL View citations (1)
32. The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
    Post-Print, HAL
33. Éditorial
    Post-Print, HAL

2017

34. Analyse des corrélations entre informatisation et performance des établissements de santé
    Post-Print, HAL
35. Assessment of a self-administered questionnaire identifying occupational exposures among lung cancer patients
    (Évaluation d’un auto-questionnaire de repérage des expositions professionnelles chez les patients atteints de cancer bronchopulmonaire)
    Post-Print, HAL View citations (2)
36. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score–Weighted Analysis
    Post-Print, HAL
37. Cost of radiotherapy: what is the quality of the evidence found? Critical quality appraisal of studies estimating cost of radiotherapy
    Post-Print, HAL
38. Does adoption of electronic health records improve organizational performances of hospital surgical units? Results from the French e-SI (PREPS-SIPS) study
    Post-Print, HAL
39. Does adoption of electronic health records improve the quality of care management in France? Results from the French e-SI (PREPS-SIPS) study
    Post-Print, HAL
40. Does adoption of electronic heath record improve the quality of care management?
    Post-Print, HAL
41. Does adoption of electronic records improve organizational performances of hospital surgical units?
    Post-Print, HAL
42. Guide méthodologique sur le calcul et l’analyse des coûts hospitaliers
    Post-Print, HAL
43. In Reply to Escande et al
    Post-Print, HAL
44. Les impacts médico-économiques de l'évolution du parcours de soins en cancérologie
    Post-Print, HAL
45. Management of Febrile Neutropenias in Adolescents and Young Adults: A Cost-Minimization Analysis Between Adult Versus Pediatric Units
    Post-Print, HAL
46. Percutaneous guided biopsy for diagnosing suspected primary malignant bone tumors in pediatric patients: a safe, accurate, and cost-saving procedure
    Post-Print, HAL
47. Radiotherapy costs: the good, the bad and the ugly
    Post-Print, HAL
48. Toxicité et qualité de vie comparées après curiethérapie par iode 125 et radiothérapie stéréotaxique des cancers prostatiques [Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers]
    Post-Print, HAL
49. Trends in occupational disparities for exposure to carcinogenic, mutagenic and reprotoxic chemicals in France 2003–10
    Post-Print, HAL View citations (2)
50. Varied exposure to carcinogenic, mutagenic, and reprotoxic (CMR) chemicals in occupational settings in France
    Post-Print, HAL View citations (6)

2016

51. A cost analysis of complex radiotherapy for patients with head and neck cancer
    Post-Print, HAL
52. A cost-effectiveness analysis of a 6-month physical activity program versus usual dietary care during adjuvant chemotherapy in breast cancer: An economic evaluation of the PASAPAS trial
    Post-Print, HAL
53. A cost-effectiveness analysis of the ZIRA test in breast cancer
    Post-Print, HAL
54. Cost Analysis of Human Genome Sequencing in Cancer Diagnosis in France: Next Generation Sequencing
    Post-Print, HAL
55. Cost evaluations of radiotherapy: What do we know? An ESTRO-HERO analysis
    Post-Print, HAL View citations (1)
56. Cost-Effectiveness Of Treatments For Mild-To-Moderate Obstructive Sleep Apnea In France
    Post-Print, HAL
57. Counterfactual approach with survival or time to event outcomes: An application to an exhaustive cohort of Epithelial Ovarian Carcinoma in the Rhône-Alps region of France
    Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon
    Also in Working Papers, HAL (2016)
58. Development of Seasonal Influenza Vaccination Recommendations: Relevance and Influence of the Evidence on the Decision-Making Process in France and the Netherlands
    Post-Print, HAL View citations (1)
59. Dossier Patient Informatisé: quel impact sur la performance des établissements de santé en France ?
    Post-Print, HAL
60. General Practitioners Perceptions About Financial and Non-Financial Incentives to Improve Influenza Vaccination Coverage Rates In France
    Post-Print, HAL
61. Guide méthodologique sur le costing à l’Hôpital
    Post-Print, HAL
62. Impact of Electronic Health Records on the Hospital Bed Occupancy Rates in Surgical Units in France: Results from the E-SI (PREPS-SIPS) Study
    Post-Print, HAL
    Also in Post-Print, HAL (2015)
63. Impact of health information systems on hospital bed occupancy rates in French hospitals: results from the e-SI (PREPS-SIPS) study
    Post-Print, HAL
64. In Reply to Fodor and Di Muzio
    Post-Print, HAL
65. Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants
    Post-Print, HAL View citations (2)
    See also Journal Article Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants, Health Policy, Elsevier (2016) View citations (2) (2016)
66. Is the Integrated Electronic Health Record Cost-Effective for a Cancer Consultation? Results from the E-SI (PREPS-SIPS) Study
    Post-Print, HAL
67. Système d'information et performance hospitalière
    Post-Print, HAL
68. Toxicity and efficacy of cetuximab associated with several modalitiesof IMRT for locally advanced head and neck cancer
    Post-Print, HAL
69. Why should we focus on a structured model of secure digital exchanges to incorporate new documents in electronic patient records?
    Post-Print, HAL

2015

70. A cost-consequence analysis of hepatitis B screening in an immigrant population
    Post-Print, HAL
71. A literature review to identify factors that determine policies for influenza vaccination
    Post-Print, HAL View citations (7)
    See also Journal Article A literature review to identify factors that determine policies for influenza vaccination, Health Policy, Elsevier (2015) View citations (7) (2015)
72. Health Information System Adoption And Hospital Accreditation Decisions In France: Results From The E-SI (PREPS-SIPS) Study
    Post-Print, HAL
73. Relationship between the development of electronic health records and hospital accreditation decisions in France: results from the E-SI (Preps-Sips)
    Post-Print, HAL

2014

74. Cost-effectiveness of a Genetic Test for Breast Cancer Risk - Letter
    Post-Print, HAL
75. Economic burden of seasonal influenza B in France during winter 2010-2011
    Post-Print, HAL
    Also in Post-Print, HAL (2013)
    Post-Print, HAL (2012)
76. Inégalités d'exposition aux agents cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France
    Working Papers, HAL
    Also in Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon (2014)
77. Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel en France
    Post-Print, HAL
78. Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: les enseignements de l'enquête SUMER
    Working Papers, HAL
79. Inégalités de l’exposition aux produits chimiques cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: les enseignements de l’enquête SUMER
    Post-Print, HAL
80. Les fortes expositions aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) sont-elles l'apanage des emplois précaires et peu qualifiés ?
    Post-Print, HAL
81. Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool
    Post-Print, HAL

2013

82. A cost-analysis of stereotactic radiotherapy in lung cancer
    Post-Print, HAL
83. Comprendre les analyses médico-économiques: intervention didactique à l'intention des cliniciens
    Post-Print, HAL
84. Cost of physical activity intervention during adjuvant chemotherapy in breast cancer: results of the randomized trial PASAPAS
    Post-Print, HAL
85. Cost of prostate image-guided radiation therapy: Results of a randomized trial
    Post-Print, HAL View citations (1)
86. Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma
    Post-Print, HAL
    Also in Post-Print, HAL (2011)
    See also Journal Article Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma, Applied Health Economics and Health Policy, Springer (2013) (2013)
87. Curiethérapie: valorisation et aspects médico-économiques
    Post-Print, HAL
88. Design of a randomised controlled trial of adapted physical activity during adjuvant treatment for localised breast cancer: the PASAPAS feasibility study
    Post-Print, HAL View citations (1)
89. Inégalités de l'exposition aux produits cancérogènes, mutagènes ou reprotoxiques (CMR) en milieu professionnel: SUMER 2010
    Post-Print, HAL
90. Literature review of the decision-making determinants related to the influenza vaccination policy
    Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon
    Also in Working Papers, HAL (2013)

2012

91. A cost-analysis of image-guided radiation therapy (IGRT) in prostate cancer: results from a phase III clinical trial
    Post-Print, HAL
92. A randomised phase II study of the efficacy, safety and cost-effectiveness of pegfilgrastim and filgrastim after autologous stem cell transplant for lymphoma and myeloma (PALM study)
    Post-Print, HAL View citations (2)
93. Cluster analysis and principal component analysis to access the variability of data in cost evaluations: methods and applications in oncology
    Post-Print, HAL
94. Cost-effectiveness analysis: an interdisciplinary research and methodological perspective
    Post-Print, HAL
95. Discordant diagnoses in sarcoma, GIST and desmoide tumour in France: results from the network RREPS
    Post-Print, HAL
96. Evaluation économique prospective de la radiothérapie guidée par l'image des cancers de la prostate dans le cadre du programme national de Soutien aux Thérapeutiques Innovantes et Coûteuses
    Post-Print, HAL
97. The use of economic evaluations in health decision-making at the macro level: a literature review
    Post-Print, HAL View citations (1)

2011

98. Adherence to practice guidelines for the management of patients with sarcoma: A cost-effectiveness assessment in two European regions
    Post-Print, HAL
99. Apports de l'évaluation médico-économique pour la décision publique en santé
    Post-Print, HAL
100. Conformity with clinical practice guidelines for management of patients with sarcoma: a cost-effectiveness assessment in two European regions
     Post-Print, HAL
101. Costi del tratamento
     Post-Print, HAL
102. Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in adult patients with lymphoma and myeloma: cost-effectiveness evaluation alongside a randomized controlled trial
     Post-Print, HAL

2010

103. Apports de l'évaluation économique et de l'analyse d'impact budgétaire pour la décision publique en santé: l'exemple du cancer du sein
     Post-Print, HAL
104. Cost-effectiveness analysis: methods and applications in oncology
     Post-Print, HAL
105. Impact of chemotherapy prescriptions and costs on survival in advanced or metastatic NSCLC: a single-institution study using an instrumental variables approach
     Post-Print, HAL

2009

106. Cost-effectiveness analysis of compliance with clinical guidelines for sarcoma management
     Post-Print, HAL
107. Costs and compliance with clinical practice guidelines: A pilot study for initial sarcoma treatment
     Post-Print, HAL
108. The effect of health care expenditures on survival in locally advanced and metastatic Non Small Cell Lung Cancer
     Post-Print, HAL
     Also in Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon (2009)
109. Transférabilité des évaluations de coûts en santé: analyse des facteurs de variabilité
     Post-Print, HAL
     See also Journal Article Transférabilité des évaluations de coûts en santé. Analyse des facteurs de variabilité, Revue économique, Presses de Sciences-Po (2009) (2009)

2008

110. A Decision-making Tool for a Costly Innovative Technology: The Case of Carbon Ion Radiotherapy
     Post-Print, HAL
111. Les évaluations de coûts en santé sont-elles transférables ?
     Post-Print, HAL
     Also in Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon (2008)
112. Short-Term cost impact of compliance with clinical practice guidelines for initial sarcoma treatment
     Post-Print, HAL
     Also in Working Papers, Groupe d'Analyse et de Théorie Economique Lyon St-Étienne (GATE Lyon St-Étienne), Université de Lyon (2008)

2007

113. Assessing the generalisability of cost evaluation results using the euclidean metric and principal components analysis: Lesson from a high-cost innovation in oncology
     Post-Print, HAL
114. Les évaluations de coûts en santé sont-elles transférables ? Mesures et application à une innovation très coûteuse en cancérologie
     Post-Print, HAL
115. Organisation et financement des soins: vers une inadéquation croissante ?
     Post-Print, HAL
116. The impact of CD34+ cell dose on the cost of HDT with PBSC transplantation in lymphomia
     Post-Print, HAL

2006

117. The contribution of the simulation for innovative technologies: The case of the hadrontherapy
     Post-Print, HAL

2005

118. A model to calculate treatment cost per protocol for light ion facility radiotherapy projects in Europe
     Post-Print, HAL
119. Report of work package 6 “Health economics aspects”
     Post-Print, HAL
120. Trajectoires optimales des patients évoluant vers la dépendance
     Post-Print, HAL

2004

121. Cost comparison of two surgical strategies in the treatment of breast cancer: Sentinel lymph node biopsy versus axillary lymph node dissection
     Post-Print, HAL
122. Light ion facility projects in Europe: methodological aspects for the calculation of the treatment cost per protocol
     Post-Print, HAL

2002

123. Vers une nécessaire harmonisation des évaluations de coûts en santé. L'exemple des intensifications thérapeutiques avec autogreffes de cellules souches du sang périphérique en France
     Post-Print, HAL

2001

124. Les apports des concepts économiques "d'équipe" et de "groupe" pour l'évaluation des réseaux de soins
     Post-Print, HAL

Journal Articles

2020

1. Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review
   PharmacoEconomics, 2020, 38, (4), 341-356 View citations (1)
   See also Working Paper Cost–Utility Analyses of Interventions for Informal Carers: A Systematic and Critical Review, Post-Print (2020) View citations (3) (2020)

2018

2. Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation
   Health Care Management Science, 2018, 21, (2), 204-223 View citations (1)
   See also Working Paper Performance and cost evaluation of health information systems using micro-costing and discrete-event simulation, Post-Print (2018) View citations (1) (2018)

2016

3. Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants
   Health Policy, 2016, 120, (3), 293-305 View citations (2)
   See also Working Paper Influenza vaccination policy-making processes in France and The Netherlands: Framework and determinants, Post-Print (2016) View citations (2) (2016)

2015

4. A literature review to identify factors that determine policies for influenza vaccination
   Health Policy, 2015, 119, (6), 697-708 View citations (7)
   See also Working Paper A literature review to identify factors that determine policies for influenza vaccination, Post-Print (2015) View citations (7) (2015)

2013

5. Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma
   Applied Health Economics and Health Policy, 2013, 11, (2), 129-138
   See also Working Paper Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma, Post-Print (2013) (2013)

2009

6. Transférabilité des évaluations de coûts en santé. Analyse des facteurs de variabilité
   Revue économique, 2009, 60, (2), 307-322
   See also Working Paper Transférabilité des évaluations de coûts en santé: analyse des facteurs de variabilité, Post-Print (2009) (2009)